Skip to content
Bored Studies
Recruiting

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

Alcyone Therapeutics, Inc · with Biogen · NCT05866419

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 3+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
90
US sites recruiting
15
Study start
November 27, 2023
Record last updated
August 19, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA).

All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.

Being studied: ThecaFlex DRx System

Conditions: Spinal Muscular Atrophy; Spine Deformity; Scoliosis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Subject is 3 years or older
  • Subject is diagnosed with SMA and is a candidate for Spinraza treatment as indicated in country-specific label
  • Subject resistant to lumbar puncture (LP), where resistance is defined as:
  • Subject with respiratory issues or other comorbidities who is at an increased risk for complications due to the need for repeat anesthesia and imaging radiation exposure to safely perform LP; or
  • Subjects for whom the treating physician determines implantation of the ThecaFlex DRx™ System is otherwise in the subject's best interest
  • Subject has been prescribed nusinersen via chronic intrathecal bolus administration in accordance with the country-specific drug labeling
  • Subject, per Investigator discretion, is able to undergo a percutaneous or open surgical procedure for index port and catheter implantation where at least 7 cm of the ThecaFlex DRx system catheter will be placed intrathecally
  • Subject (or subject's legally authorized representative) is willing and able to provide written informed consent; and
  • Subject and parent/caregiver able and willing to complete all clinical investigation procedures, measurements, and visits.

Exclusion Criteria

  • Subject meets any of the contraindications for use of the ThecaFlex DRx System as outlined in the ThecaFlex DRx System Instructions for Use
  • Presence or history of (\< 6 months prior to the procedure): an implanted microinfusion pump, intrathecal catheter, or other intrathecal drug delivery devices/component, or implanted shunt for drainage of cerebrospinal fluid (CSF), or reservoir in the CSF space (note: any ThecaFlex Port and Catheter System must not be placed in the same location as a previous indwelling port and catheter)
  • Subject is pregnant or nursing or plans to become pregnant during the course of the clinical investigation, or is a woman of childbearing potential or a man of reproductive age who is unwilling or unable to practice contraception, as described in Section 14.10.
  • Any condition or event, which in the opinion of the Investigator may adversely affect the safety and effective implantation and use of the ThecaFlex DRx system or confound the clinical investigation, including:
  • Severe structural impediment that may preclude safe implantation of the catheter and port
  • Major medical events (as defined per investigator's discretion) within 60 days prior to screening; or
  • Relevant surgeries (e.g., head and neck, back, etc.) within 60 days prior to screening or planned during the duration of the clinical investigation
  • Space-occupying lesion with mass effect
  • Posterior fossa mass
  • Arnold-Chiari malformation
  • Coagulation abnormalities and/or thrombocytopenia
  • Insufficient or inadequate skin or underlying fat to adequately protect the port or enough surface area to allow the skin to close safely
  • Subject is contraindicated for administration of nusinersen per its approved country-specific labeling
  • History of intrathecal granuloma formation
  • History of bacterial meningitis or aseptic meningitis within 6 months of screening
  • History of tumors or other spinal abnormalities documented by magnetic resonance imaging (MRI) or computed tomography (CT) that would interfere with the catheter implantation procedures or CSF circulation
  • History of hydrocephalus
  • Diagnosed degenerative muscular disease other than SMA
  • History of depression, cognitive impairment, or another psycho-behavioral problem that in the opinion of the Investigator may preclude safe participation in the clinical investigation and
  • Serious medical condition that, in the opinion of the investigator, may lead to reduced life expectancy beyond 12 months.
  • Subject is involved in another Investigation Device Exemption Study.
  • Subject has clinically meaningful immunosuppression, in the opinion of the investigator, either from therapy or a comorbid condition, which, in the opinion of the investigator, makes them a poor surgical candidate due to increased risk of infection.

Recruiting US locations

  • Barrow Neurological Institute

    Phoenix, AZ 85013

    Site contact: Kathleen Nagaran Hildebrand · (602) 406 7031 · kathleen.nagaranhildebrand900@commonspirit.org

  • Children's Hospital Orange County

    Orange, CA 92868

    Site contact: Melina Thaxton · MelinaThaxton@choc.org

  • Stanford Medical Center

    Palo Alto, CA 94301

    Site contact: Habib Mofakham · neuromuscularresearch@stanford.edu

  • Rady Children's Hospital

    San Diego, CA 92037

    Site contact: Elizabeth Moreno · e4moreno@health.ucsd.edu

  • Nemours Children's Hospital, Florida

    Orlando, FL 32827

    Site contact: Debbie Berry · debbie.berry@nemours.org

  • Lurie Childrens Hospital

    Chicago, IL 60611

    Site contact: Raven HIll

  • Boston Children's Hospital

    Boston, MA 02115

    Site contact: Adam Porter · adam.porter@childrens.harvard.edu

  • Helen DeVos Children's Hospital

    Grand Rapids, MI 49503

    Site contact: Natasha Schafer · natasha.schafer@corewellhealth.org

  • Columbia University Irving Medical Center/NewYork Presbyterian Hospital

    New York, NY 10032

    Site contact: Kimbery Berry · 212-342-3038 · KB2996@cumc.columbia.ediu

  • UH Rainbow Babies and Children's Hospital

    Cleveland, OH 44106

    Site contact: Abigail Schlosser · Abigail.Schlosser@UHhospitals.org

  • Penn State Milton S. Hershey Medical Center

    Hershey, PA 17033

    Site contact: Chelsea Emrick · awinters2@pennstatehealth.psu.edu

  • Children's Hospital Philadelphia

    Philadelphia, PA 19104

    Site contact: Samantha Gogel · Gogels@chop.edu

  • Texas Children's Hospital

    Houston, TX 77030

    Site contact: Sarah Wisor · sxwisor@texaschildrens.org

  • University of Virginia

    Charlottesville, VA 22903

    Site contact: Chelsea Masterson

  • Childrens Hospital of the King's Daughters

    Norfolk, VA 23510

    Site contact: Erika Paradiso · Erika.Paradiso@chkd.org

Study contacts (from the official record)

  • Janelle Arrambide · 857-500-7526 · janelle.arrambide@biogen.com
Study of an Intrathecal Port and Catheter System for Subjects With… (NCT05866419) | Bored Studies